Summary
Healthy human coronary artery walls contain, over their entire lifetime, more free and total cholesterol than calcium. However, as soon as arteriosclerotic alterations set in, the calcium content increases. Thus in coronary fatty streaks (arteriosclerotic plaques of WHO stage I), calcium was increased 13 times, in stage II plaques 25 times, and in fully developed stage III plaques 80 times above normal on average. The most dramatic calcium incrustation was found in coronary stage III plaques that had produced massive fatal coronary infarction. Here, the proportion of calcium salts (particularly hydroxyapatite) may amount to almost 50% of dry weight. Thus the most excessive accumulation of calcium seems to be correlated with the highest fatality. In contrast, there is no correlation between mural coronary free or total cholesterol content, and plaque severity. Accordingly, stenosing coronary stage III plaques contain less cholesterol than do fatty streaks. Moreover, in coronary stage III plaques the proportion of free cholesterol was 1.37%, and of total cholesterol only 2.34% of the whole mass, certainly not enough for directly causing coronary occlusion. Thus the calcium-rich plaques of human coronary arteries considerably differ from the well-known cholesterol-rich plaques (stage I and II) of human aortae. Our findings justify a new prophylactic approach with suitable calcium antagonists, to interfere with deleterious calcium uptake in coronary plaque development.
Similar content being viewed by others
References
Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity.J. Biol Chem. 1952;195:357–366.
Donike M, Schänzer W. Private communication (in press).
McGill HC Jr. Characterization of atherosclerotic lesions as they pertain to noninvasive, techniques. In: Hegyeli RJ, ed.Atherosclerosis reviews, vol. 10: Noninvasive methods in atherosclerosis research. New York: Raven Press, 1983:1–5.
Small DM. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. George Lyman Duff Memorial Lecture.Arterioslcerosis 1988;8:103–129.
Anitschkow N, Chalatow S. Über experimentelle Cholesterinsteatose und ihre Bedeutung für die Entstehung einiger pathologischer Prozesse.Zentralbl f Allgemeine Pathol u Anat 1913;14:1–9.
Katase A. Experimentelle Verkalkung am gesunden Tiere.Beiträge Path Anat und Allg Path 1913;57:516–550.
Herzenberg H. Studien über die Wirkungsweise des bestrahlten Ergosterins (Vigantol) und die Beziehungen der von ihm gesetzten Veränderungen zur Arteriosklerose.Beitr Path Anat, 1929;82:27–56.
Hass GM, Trueheart RE, Hemmens A. Experimental arteriosclerosis due to hypervitaminosis D.Am J Pathol 1960;37:521–539.
Eisenstein R, Zeruolis L. Vitamin-D-induced aortic calcification.Arch Pathol 1964;77:27–35.
Yogamundi Moon J. Factors affecting arterial calcification associated with atherosclerosis. A review.Atherosclerosis 1972;16:119–126.
Fleckenstein A, Kammermeier H, Döring HJ, et al.. Zum Wirkungsmechanismus neuatiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokard-Effekten, Prenylamin und Iproveratril.Z.f. Kreislaufforsch 1967;56:716–744, 839–858.
Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie L, eds.Calcium and the heart. Proceedings of the Meeting of the European Section of the International Study Group for Research in Cardiac Metabolism, London, September 1970. London: Academic Press, 1971:135–188.
Flekenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.Ann Rev Pharmacol. Toxicol 1977;17:149–166.
Fleckenstein A.Calcium antagonism in heart and smooth muscle—experimental facts and therapeutic prospects. Monograph, New York: John Wiley, 1983.
Fleckenstein A. History of calcium antagonists. In: Schwartz A, Taira N, eds.Calcium channel blocking drugs: a novel intervention for the treatment of cardiac disease, Monograph No. 95 of the American Heart Association.Circ Res 52:1983;3–16.
Kohlhardt M, Bauer B, Krause H, Fleckenstein A. Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibers by the use of specific inhibitors.Pflügers Arch Physiol 1972;335:309–322.
Fleckenstein A, Janke J, Döring HJ, Pachinger O. Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions. In: Bajusz E, Rona G, eds.Cardiomyopathies, Vol. 2, Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1973:455–466.
Fleckenstein A, Janke J, Döring HJ, Leder O. Myocardial fibre necrosis due to intracellular Ca overload—a new principle in cardiac pathophysiology. In: Dhalla NS, ed.Myocardial Biology. Vol. 4, Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1974:563–579.
Fleckenstein A, Janke J, Döring HJ, Leder O. The key role of Ca in the production of noncoronarogenic myocardial necroses. In: Fleckenstein A, Rona G, eds.Pathophysiology and morphology of myocardial cell alterations. Vol 6. Recent advances in studies on cardiac structure and metabolism. Baltimore: University Park Press, 1975:21–32.
Janke J, Hein B, Pachinger O. et al. Hemmung arteriosklerotischer Gefässprozesse durch prophylaktische Behandlung mit MgCl2, KCl und organischen Ca++-Antagonisten (quantitative Studien mit45Ca bei Ratten). In: Betz E ed.Vascular smooth muscle, verh satel symp XXV internat congr physiol wissenschaften, Tübingen, Juli 1971. Berlin: Springer Verlag, 1972:71–72.
Frey M, Keidel J, Flekenstein A. Verhütung experimenteller Gefässverkalkungen (Mönckeberg's Typ der Arteriosklerose) durch Calcium-Antagonisten bei Ratten In: Fleckenstein A, Roskamm H, eds.Calcium-antagonismus, Proceed Internat Symp in Frankfort, 1978. Berlin: Springer Verlag, 1980:258–264.
Fleckenstein A, Frey M, Fleckenstein-Grün G. Protection by calcium antagonists against experimental arterial calcinosis. In: Pyörälä K et al., eds.Secondary prevention of coronary heart disease. Workshop of the Internat. Soc. and Federation of Cardiology, Titisee, Oct 1983. Stuttgart: G. Thieme Verlag, 1983:109–122.
Fleckenstein A, Frey M, Leder O. Prevention by calcium antagonists of arterial calcinosis. In: Fleckenstein A et al., eds.Drug development and evaluation—New calcium antagonists—Recent developments and prospects. Diltiazem Workshop, Freiburg/Germany, May 1982. Stuttgart: Gustav Fischer Verlag, 1983:15–31.
Fleckenstein A, Frey M, v. Witzleben H. Vascular calcium overload—A pathogenetic factor in arteriosclerosis and its neutralization by calcium antagonists. In: Kaltenbach M, Neufeld HN, eds.New therapy of ischemic heart disease and hypertension. Proceed. of the 5th Internat. Adalat Symp. Berlin, May 1982, Amsterdam: Excerpta Medica, 1983:36–52.
Fleckenstein A, Frey M, Fleckenstein-Grün G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists.Am J Cardiol 1986;57:1D-10D.
Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.Am J Cardiol 1985;56:3H-14H.
Fleckenstein A, Fleckenstein-Grün G, Frey M, Zorn J. Future directions in the use of calcium antagonists.Am J Cardiol 1987;59:177B-187B.
Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis.Trends Pharmacol Sci (TIPS) 1987;8:496–501.
Fleckenstein A. Model experiments on anticalcinotic and antiarteriosclerotic arterial protection with calcium antagonists.J Mol Cell Cardiol 1987:19(Suppl II):109–121.
Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G, Calcium, a neglected key factor in hypertension and arteriosclerosis. Experimental vasoprotection with calcium antagonists or ACE inhibitors. In: Laragh JH, Brenner BM eds.Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:471–509.
Lichtlen P. Antisclerotic effects of nifedipine: The INTACT-study. In:New trends, aspects, and long-term benefits of calcium antagonists-Focus on Adalat. Proceedings of a Symposium in Vancouver, April 1989.Cardiovasc Drugs Ther Boston: Kluwer Academic Publishers, in press.
Kober G, Schneider W, Kaltenbach M. Can the progression of coronary sclerosis be influenced by calcium antagonists?J Cardiovasc Pharmacol 1989;13:S2-S6.
Weinstein DB, Heider JG. Antiatherogenic properties of calcium antagonists.Am J Cardiol 1987;59:163B-172B.
Weinstein DB. Protective effects of calcium channel antagonists in experimental models of atherogenesis and vascular disease. In: Laragh JH, Brenner BM, eds.Hypertension: Pathophysiology, diagnosis, and management. New York: Raven Press, 1990:511–519.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fleckenstein, A., Frey, M., Thimm, F. et al. Excessive mural calcium overload — A predominant causal factor in the development of stenosing coronary plaques in humans. Cardiovasc Drug Ther 4 (Suppl 5), 1005–1013 (1990). https://doi.org/10.1007/BF02018309
Issue Date:
DOI: https://doi.org/10.1007/BF02018309